Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
Hadfield, K D
Wardley, Andrew M
Evans, D G
Roberts, S A
Newman, W G
AffiliationDepartment of Medical Oncology, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.
MetadataShow full item record
AbstractSingle nucleotide polymorphisms (SNPs) in the gene encoding aromatase (CYP19A1) have been associated with differential benefit from letrozole treatment in metastatic breast cancer (mBC) patients, but validation is lacking. The aim was to investigate whether polymorphic variation of CYP19A1 and enzymes involved in estrogen and aromatase inhibitors (AIs) metabolism are associated with efficacy of AIs. 308 Women with estrogen-receptor-positive metastatic mBC treated with a third-generation AI were identified retrospectively. DNA was extracted from archival formalin-fixed paraffin embedded tumors and genotyped for 71 variants in 16 candidate genes, including CYP19A1. Time to treatment failure (TTF) was significantly improved in patients carrying the minor (T) allele of rs4775936 when compared to patients with the reference allele [HR = 0.79 per T allele (0.66-0.95); P = 0.012]. Patients with >7 TTTA repeats on either allele of CYP19A1 intron 4 had a lower risk of failure than those with a smaller repeat size [HR = 0.84 per >7 TTTA repeats (0.7-0.99); P = 0.04]. However, importantly in multivariate analysis, adjusting for the number of disease sites; disease-free interval from diagnosis to first recurrence, grade at diagnosis and first recurrence type neither variant maintained independent predictive significance. None of the 56 SNPs analyzed as an exploratory set showed significant association with TTF. Variants in CYP19A1 or other selected genes associated with AI metabolism were not independently associated with improved AI efficacy and emphasize the importance in pharmacogenetic studies of considering genetic biomarkers in the context of relevant prognostic factors.
CitationPolymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. 2012,133(3):1191-8 Breast Cancer Res Treat
JournalBreast Cancer Research and Treatment
- Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
- Authors: Park IH, Lee YS, Lee KS, Kim SY, Hong SH, Jeong J, Lee H, Ro J, Nam BH
- Issue date: 2011 Nov
- Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.
- Authors: Miron L, Negură L, Peptanariu D, Marinca M
- Issue date: 2012 Oct-Dec
- Pharmacogenetics of aromatase inhibitors.
- Authors: Hadfield KD, Newman WG
- Issue date: 2012 Apr
- Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
- Authors: Lunardi G, Piccioli P, Bruzzi P, Notaro R, Lastraioli S, Serra M, Marroni P, Bighin C, Mansutti M, Puglisi F, Porpiglia M, Ponzone R, Bisagni G, Garrone O, Cavazzini G, Clavarezza M, Del Mastro L
- Issue date: 2013 Jan
- A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.
- Authors: Liu L, Bai YX, Zhou JH, Sun XW, Sui H, Zhang WJ, Yuan HH, Xie R, Wei XL, Zhang TT, Huang P, Li YJ, Wang JX, Zhao S, Zhang QY
- Issue date: 2013 Sep 13